1. Home
  2. RVSN vs ENSC Comparison

RVSN vs ENSC Comparison

Compare RVSN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$3.10

Market Cap

7.9M

Sector

N/A

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.52

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
ENSC
Founded
2016
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.6M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
RVSN
ENSC
Price
$3.10
$0.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
★ 523.6K
Earning Date
08-26-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 65.24
EPS
★ N/A
N/A
Revenue
N/A
★ $5,066,650.00
Revenue This Year
$169.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.23
52 Week High
$9.39
$2.26

Technical Indicators

Market Signals
Indicator
RVSN
ENSC
Relative Strength Index (RSI) 41.33 57.92
Support Level $0.24 $0.47
Resistance Level $5.09 $0.53
Average True Range (ATR) 0.28 0.05
MACD 0.02 0.00
Stochastic Oscillator 33.32 56.57

Price Performance

Historical Comparison
RVSN
ENSC

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: